Accumulating evidence for epicardial ablation in malignant forms of Brugada syndrome: summary of two randomized clinical trials
- PMID: 40590688
- PMCID: PMC12210372
- DOI: 10.1093/europace/euaf116
Accumulating evidence for epicardial ablation in malignant forms of Brugada syndrome: summary of two randomized clinical trials
Conflict of interest statement
Conflict of interest: none declared.
Comment on
-
Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial.Europace. 2025 May 7;27(5):euaf097. doi: 10.1093/europace/euaf097. Europace. 2025. PMID: 40401314 Free PMC article. Clinical Trial.
References
-
- Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391–6. - PubMed
-
- Marsman EMJ, Postema PG, Remme CA. Brugada syndrome: update and future perspectives. Heart 2022;108:668–75. - PubMed
-
- Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL et al. Long-term prognosis of patients diagnosed with Brugada syndrome. Results from the FINGER Brugada syndrome registry. Circulation 2010;121:635–43. - PubMed
-
- Behr ER, Winkel BG, Ensam B, Alfie A, Arbelo E, Berry C et al. The diagnostic role of pharmacological provocation testing in cardiac electrophysiology. A clinical consensus statement of the European heart rhythm association (EHRA) and the European association of percutaneous cardiovascular interventions (EAPCI) of the ESC, the ESC working group on cardiovascular pharmacotherapy, the association of paediatric and congenital cardiology (AEPC), the paediatric & congenital electrophysiology society (PACES), the heart rhythm society (HRS), the Asian Pacific heart rhythm society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace 2025;27:euaf067. - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources